Abstract:Introduction: The aromatase enzyme plays an important role in the progress of hormone-dependent breast cancer, especially in estrogen receptor-positive (ER+) breast cancers. In case of postmenopausal women, the aromatization of androstenedione to estrone in adipose tissue is the most important source of estrogen. Generally 60%-75% of pre- and post-menopausal women suffer from estrogen-dependent breast cancer, and thus suppressing estrogen has been recognized to be a successful therapy. Hence, to limit the stimulation of estrogen, aromatase inhibitors (AIs) are used in the second-line treatment of breast cancer. Methods: The present computational study employed an in silico approach in the identification of natural actives targeting the aromatase enzyme from a structurally diverse set of natural products. Molecular docking, QSAR studies and pharmacophore modeling were carried out using the VLife Molecular Design Suite (version 4.6). The stability of the compounds was confirmed by molecular dynamics. Results: From molecular docking and analysis of interactions with the amino acid residues of the binding cavity, it was found that the amino acid residues interacting with the non-steroidal inhibitors exhibited π-stacking interactions with PHE134, PHE 221, and TRP 224, while the steroidal drug exemestane lacked π-stacking interactions. QSAR studies were performed using the flavonoid compounds, in order to identify the structural functionalities needed to improve the anti-breast cancer activity. Molecular dynamics of the screened hits confirmed the stability of compounds with the target in the binding cavity. Moreover, pharmacophore modelling presented the pharmacophoric features of the selected scaffolds for aromatase inhibitory activity. Conclusion: The results presented 23 hit compounds that can be developed as anti-breast cancer modulating agents in the near future. Additionally, anthraquinone compounds with minor structural modification can also serve to be potential aromatase inhibitors. The in silico protocol utilised can be useful in the drug discovery process for development of new leads from structurally diverse set of natural products that are comparable to the drugs used clinically in breast cancer therapy.

Design, Synthesis and Activity of Flavonoids Aromatase Inhibitors

Syntheses and Qsar Studies of Benzylimidazole Derivatives and Benzylcarbazole As Potential Aromatase Inhibitors

Prenylflavonoids as nonsteroidal phytoestrogens and related structure-activity relationships.

Characterization Of Aromatase Binding Agents From The Dichloromethane Extract Of Corydalis Yanhusuo Using Ultrafiltration And Liquid Chromatography Tandem Mass Spectrometry

Screening for Aromatase Ligands in the Extract of Broussonetia Papyrifera Using High Performance Liquid Chromatography and ESI-mass Spectrometry

Screening for Ligands of Human Aromatase from Mulberry (mori Alba L.) Leaf by Using High-Performance Liquid Chromatography/tandem Mass Spectrometry

Polyphenolic natural products and natural product–inspired steroidal mimics as aromatase inhibitors

Synthesis of Flavone Derivatives via N-Amination and Evaluation of Their Anticancer Activities

Synthesis and Estrogen-Like Activity of Resveratrol Analogues

Computational studies and structural insights for discovery of potential natural aromatase modulators for hormone-dependent breast cancer

Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer

Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs

Two Natural Products, Trans-Phytol and (22E)-Ergosta-6,9,22-triene-3β,5α,8α-triol, Inhibit the Biosynthesis of Estrogen in Human Ovarian Granulosa Cells by Aromatase (CYP19)

Unlocking the potential of aromatase inhibitors: recent advances in drug design, synthesis, docking activity, and in vitro bioactivity evaluations

Two Natural Products, Trans-Phytol And (22e)-Ergosta-6,9,22-Triene-3 Beta,5 Alpha,8 Alpha-Triol, Inhibit The Biosynthesis Of Estrogen In Human Ovarian Granulosa Cells By Aromatase (Cyp19)

Origin of aromatase inhibitory activity via proteochemometric modeling

Aromatase inhibition and inactivation

Synthesis, In vitro and In silico Studies of Novel bis‐triazolopyridopyrimidines from Curcumin Analogues as Potential Aromatase Agents

Synthesis, Docking Studies and Biological Activity of New Benzimidazole- Triazolothiadiazine Derivatives as Aromatase Inhibitor

Design, Syntheses and Biological Evaluation of Natural Product Aiphanol Derivatives and Analogues: Discovery of Potent Anticancer Agents

Design, synthesis, biological activity evaluation and structure-activity relationships of new steroidal aromatase inhibitors. The case of C-ring and 7β substituted steroids